NCT03707990 - A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

August 13, 2019

Study Completion Date

August 13, 2019

Conditions

Obesity and Overweight

Interventions

DRUG

NNC0165-1875

Participants will receive a single dose of subcutaneous (s.c.) NNC0165-1875 injection. The planned doses of NNC0165-1875 are as following: cohort 1 and 7: 0.1 mg, cohort 2 and 8: 0.3 mg, cohort 3 and 9: 0.6 mg, cohort 4 and 10: 1.2 mg, cohort 5 and 11: 2.4 mg and cohort 6: 0.03 mg.

DRUG

Placebo (NNC0165-1875)

Participants will receive a single dose of s.c. placebo injection.

DRUG

Semaglutide

Participants will receive a single dose of s.c. semaglutide 0.25 mg injection.

Trial Locations (1)

85283

Novo Nordisk Investigational Site, Tempe